CeASE trial probes a sympathetic block for post-COVID autonomic symptoms
A new randomized controlled trial is set to test whether interrupting the cervicothoracic sympathetic chain can ease post-COVID condition symptoms linked to autonomic dysfunction. The CeASE study pairs an ultrasound-guided cervicothoracic sympathetic chain block with a sham comparator of normal saline delivered through the same procedural route, a design intended to separate a true physiologic effect from the ritual and expectation attached to a deep neck injection.
The protocol is tightly built around masking. Participants, proceduralists, and outcome assessors are blinded, and the trial adds a formal blinding check by asking both participants and proceduralists to guess allocation and rate their confidence. In a field where symptom burden is subjective and placebo response can be substantial, that extra layer matters. It also acknowledges a basic clinical truth: when a procedure is invasive and attention-rich, the procedure itself can become part of the treatment signal unless the control arm is crafted with unusual care.
Why the sympathetic chain is being targeted
Post-COVID illness has left many patients with autonomic complaints that are difficult to pin to a single organ system. Symptoms can be diffuse, fluctuating, and hard to capture with one laboratory marker or one questionnaire. The CeASE investigators are betting that a cervical sympathetic intervention may modify a physiologic pathway involved in autonomic instability, rather than simply quieting symptoms through reassurance or procedural expectation.
A sympathetic block is not a generic analgesic maneuver. It is designed to alter nerve signaling in a region where autonomic outflow is concentrated, and that makes it a plausible candidate when the clinical problem includes cardiovascular dysregulation, symptom provocation with exertion, or other signs of autonomic imbalance. Whether that translates into measurable benefit in a heterogeneous post-COVID cohort is the question the study is built to answer.
A control arm built to match the procedure, not just the needle
The comparator is not a minimal intervention. Investigators are using an ultrasound-guided injection of normal saline delivered in the same procedural fashion, which controls for the tactile experience of the intervention, the time spent in the procedure suite, the ultrasound guidance, and the expectation that often accompanies a specialized injection. In procedural trials, those non-specific factors can be powerful enough to blur interpretation if the control is too simple.
Here, the saline arm is doing important scientific work. It creates a direct test of whether the active block provides benefit beyond the experience of receiving a carefully performed neck injection. For a condition with variable symptoms and no single definitive biomarker, that distinction is essential to clinical credibility.
Mixed endpoints reflect a mixed syndrome
The outcome strategy combines a validated condition-specific patient-reported measure with objective cardiovascular autonomic testing, serum proinflammatory cytokines, and wearable actigraphy. That mix mirrors the clinical reality of post-COVID condition, where one patient may primarily report exercise intolerance, another may describe palpitations and lightheadedness, and another may show little on a standard exam but substantial impairment in daily activity.
Using both subjective and objective measures is a strength because it keeps the trial from depending on one narrow readout. Patient-reported outcomes capture burden and function, while autonomic testing can register physiologic change, cytokines may help explore inflammatory biology, and actigraphy offers a window into real-world movement and activity patterns. If the intervention works, the signal may not appear in only one domain. If it fails, the combination of endpoints should help clarify whether the problem is symptom perception, autonomic physiology, or both.
The endpoint structure also makes clear what this protocol is not: it is not a simple before-and-after symptom survey. It is a mechanistic clinical trial designed to ask whether a nerve-targeting procedure can shift the physiologic and daily-life profile of post-COVID illness.
Heterogeneity is built into the entry criteria
Eligibility requires only a Composite Autonomic Symptom Score-31 score greater than 0 in one domain. That broad threshold will likely draw in participants with different symptom patterns and different levels of severity. Some may have relatively mild autonomic complaints, while others may have more substantial dysfunction. Some may have one prominent domain of symptoms rather than a uniform syndrome.
This matters because autonomic phenotypes are rarely neat in practice. A study that enrolls a broad post-COVID population can be more representative of the clinic, but it can also dilute a treatment effect if only a subset is biologically responsive. The protocol accepts that tradeoff. It gains access to the real-world variability of post-COVID illness while risking a less uniform response signal.
Limits on generalizability are already visible in the protocol
Recruitment is limited to two Canadian tertiary centres, and participants must be English-speaking. Several comorbidities common in post-COVID condition are excluded. Those design choices may make the sample cleaner for internal validity, but they also narrow the population that can be confidently mapped onto routine practice.
A procedure trial with this level of masking and endpoint depth can still leave open questions about external validity. Patients seen outside tertiary referral centers may differ in symptom burden, access to evaluation, comorbid disease, language background, and prior care pathways. The exclusion of common comorbidities may also remove precisely the patients clinicians most often see in day-to-day practice.
What this protocol can answer, and what it cannot yet
For now, CeASE is a study protocol, not an outcomes report. Its value lies in how carefully it is built: blinding on all sides, a saline control matched to the active procedure, and a multi-layered endpoint package that reaches from symptoms to activity monitoring to autonomic physiology. The design is strong enough to determine whether a cervicothoracic sympathetic chain block deserves a place in the next stage of post-COVID research.
One sentence captures the whole uncertainty: this trial is asking whether a targeted sympathetic intervention can produce benefit beyond a well-matched sham procedure in a heterogeneous post-COVID population.
If the study reads positive, interpretation will still depend on how large the effect is, whether it appears across symptom and physiologic endpoints, and which patients are driving the signal. If it is neutral, the combination of blinded procedural control and objective measures should still help distinguish a true lack of efficacy from a placebo-heavy procedural effect. Either way, the protocol gives the field a disciplined way to test a therapy that sits at the intersection of autonomic medicine, symptom science, and post-viral care.